Hedgehog pathway inhibitors: A patent review (2009-present)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 3, 2013, Pages 345-361

  Hadden, Matthew Kyle ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Basal cell carcinoma; Cancer; Gli; Hedgehog signaling; Medulloblastoma; Smoothened

Indexed keywords

AKI 0532; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BMS 833923; BRD 6851; FURAN DERIVATIVE; HEDGEHOG PATHWAY INHIBITOR; HISTONE DEACETYLASE INHIBITOR; ITRACONAZOLE; LY 2940680; MK 5710; MRT 10; MRT 14; MS 0022; PF 04449913; PF 5274857; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN INHIBITOR; PYRIDAZINE DERIVATIVE; PYRROLO (3,2 C)QUINOLONE 4 ONE; ROBOTNIKIN; SANT 74; SANT 75; SARIDEGIB; SEN 450; SONIDEGIB; TAK 441; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISMODEGIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; BREAST CANCER; CANCER RESISTANCE; DOWN REGULATION; DRUG IDENTIFICATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; GLIOBLASTOMA; HIGH THROUGHPUT SCREENING; HUMAN; LEUKEMIA; LYMPHOMA; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATENT; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; HEDGEHOG PROTEINS; HUMANS; MEDULLOBLASTOMA; PATENTS AS TOPIC; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874059433     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.757304     Document Type: Review

References (99)

1. Yang L, Xie G, Fan G, et al. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 2010;29:469-81
2. Epstein EH. Basal cell carcinoma: Attack of the hedgehog. Nat Rev Cancer 2008;8:743-54
3. Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002;297:1559-61
4. Ling G, Ahmadian A, Persson A, et al. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene 2001;20:7770-8
5. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH, and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005;152:43-51
6. Klesse LJ, Bowers DC. Childhood medulloblastoma: Current status of biology and treatment. CNS Drugs 2010;24:285-301
7. Pan E, Pellarin M, Holmes E, et al. Isochrome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 2005;11:4733-40
8. Di Marcotullio L, Ferretti E, De Smaele E, et al. RENKCTD11 is a suppressor of hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci 2004;101:10833-8
9. De Smaele E, Di Marcotullio L, Ferretti E, et al. Chromosome 17p deletion in human medulloblastoma: A missing checkpoint in the hedgehog pathway. Cell Cycle 2004;3:1263-6
10. Tostar U, Malm CJ, Meis-Kindblom JM, et al. Deregulation of the hedgehog signalling pathway: A possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J Pathol 2006;208:17-25
11. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-6
12. Watkins DN, Berman DM, Burkholder SG, et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003;422:313-17
13. Varnat F, Duquet A, Malerba M, et al. Human colon cancer epithelial cells harbor active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 2009;1:338-51
14. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003;425:846-51
15. Bhattacharya R, Kwon J, Ali B, et al. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res 2008;14:7659-66
16. Tiet TD, Hopyan S, Nadesan P, et al. Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol 2006;168:321-30
17. Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004;431:707-12
18. Li Y, Maitah MY, Ahmad A, et al. Targeting the hedgehog signalling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:49-66
19. Teglund S, Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 2010 ;1805:181-208
20. Merchant AA, Matsui W. Targeting hedgehog - a cancer stem cell pathway. Clin Cancer Res 2010;16:3130-40
21. Ng JM, Curran T. The hedgehog's tale: Developing strategies for targeting cancer. Nat Rev Cancer 2011;11:493-501
22. Tremblay MR, Nesler M, Weatherhead R, Castro AC. Recent patents for hedgehog pathway inhibitors for the treatment of malignancy. Expert Opin Ther Patents 2009 ;19:1039-56
23. A summary of the information that led to the FDA Approval of GDC-0449 (Vismodegib). Available from: http:// www.cancer.gov/cancertopics/druginfo/ fda-vismodegib 24. Allison M. Hedgehog hopes lifted by approval and stung by failure. Nat Biotech 2012;30:203
24. Yauch RL, Dijkgraaf GJP, Alicke B, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-4
25. Dijkgraaf GJP, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011;71:435-44
26. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pthway in medulloblastoma. Sci Transl Med 2010 ;2:51ra70
27. Wang J, Lu J, Bond MC, et al. Identification of select glucocorticoids as smoothened agonists: Potential utility for regenerative medicine. Proc Natl Acad Sci 2010;107:9323-8
28. Wang Y, Davidow L, Arvanites AC, et al. Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity. Chem Biol 2012;19:972-82
29. Wu VM, Chen SC, Arkin MR, et al. Small molecule inhibitors of smoothened ciliary localization and ciliogenesis. Proc Natl Acad Sci 2012;109:13644-9
30. The Board of Trustees the Leland Stanford Junior University. Hedgehog pathway antagonists and methods of use. WO2010141680 ; 2010
31. Hyman JM, Firestone AJ, Heine VM, et al. Small-molecule inhibitors reveal multiple strategies for hedgehog pathway blockade. Proc Natl Acad Sci 2009;109:14132-7
32. Stanton BZ, Peng LF, Maloof N, et al. A small molecule that binds hedgehog and blocks its signaling in human cells. Nat Chem Biol 2009;5:154-6
33. Wang Y, Arvanites AC, Davidow L, et al. Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation. ACS Chem Biol 2012;7:1040-8
34. President and Fellows of Harvard College and the General Hospital Corp. Sonic hedgehog modulators. WO2009132032 ; 2009
35. Dockendorff C, Nagiec MM, Weiwer M, et al. Macrocyclic hedgehog pathway inhibitors: optimization of cellular activity and mode of action studies. ACS Med Chem Lett 2012;3:808-13
36. Kim W-K, Meliton V, Park KW. Negative regulation of hedgehog signaling by liver X receptors. Mol Endocrinol 2009;23:1532-43
37. Baranowski M. Biological role of liver X receptors. J Physiol Pharmacol 2008;59(Suppl 7):31-55
38. The Regeants of the University of California, The Johns Hopkins University. Oxysterols that activate liver X receptor signaling and inhibit hedgehog signaling. WO2011103175 ; 2011
39. Pamlico Pharmaceutical, Inc. 2-arylimidazo[1,2-B]pyridazine, 2-phenylimidazo[1,2-A]pyridine, and 1-phenylimidazo[1,2-A]pyrazine derivatives. WO2012088411 ; 2012
40. From the Pamlico Pharmaceutical Hedgehog Program Fact Sheet. Available from: http://www.pamlicopharma.com/ Home/research 42. Amgen, Inc. Pyridopyridazine compounds, compositions and methods of use. US20090099173; 2009
41. Kaizerman JA, Aaron W, An S, et al. Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagnoists using novel pyridopyridazines. Bioorg Med Chem Lett 2010;20:4607-10
42. Amgen, Inc. Phthalazine compounds, compositions and methods of use. WO2009002469 ; 2009
43. Novartis AG. Pyridazine derivatives as Smo inhibitors. WO2010007120 ; 2010
44. Novartis AG. Formulations of a pyridazine bipyrazinyl. WO2011130500 ; 2011
45. Eli Lilly and Co. Tetrasubstituted pyridazine hedgehog pathway antagonists. WO2010056588 ; 2010
46. Eli Lilly and Co. Tetrasubstituted pyridazines hedgehog pathway antagonists. WO2010056620 ; 2010
47. Eli Lilly and Co. Disubstituted phthalazine hedgehog pathway antagonists. WO2010147917 ; 2010
48. Miller-Moslin K, Peukert S, Jain RK, et al. 1-Amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. J Med Chem 2009;52:3954-68
49. Bender MH, Hipskind PA, Capen AR, et al. Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling [Abstract 2819]. 102nd AACR Meeting 2011;131:E33-44
50. A description of the clinical trial. Available from: http://www. clinicaltrials. gov/ct2/show/NCT01226485? term=LY2940680&rank=4.
51. Istituto Di Ricerche Di Biologia Molecolare. 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as Smo antagonists. WO2010013037 ; 2010
52. Ontoria JM, Bufi LL, Torrisi C, et al. Identification of a series of 4-[3-quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors. Bioorg Med Chem Lett 2011;21:5274-82
53. Muraglia E, Ontoria JM, Branca D, et al. N-(2-alkylaminoethyl)-4-(1,2,4- oxadiazol-5-yl)piperazine-1-carboxamides as highly potent smoothened antagonists. Bioorg Med Chem Lett 2011;21:5283-8
54. Istituto Di Ricerche Di Biologia Molecolare. Piperidine and piperazine derivatives as Smo antagonists. WO2011036478 ; 2011
55. Istituto Di Ricerche Di Biologia Molecolare. Saturated bicyclic heterocyclic derivatives as Smo antagonists. WO2010023480 ; 2010
56. Istituto Di Ricerche Di Biologia Molecolare. Unsaturated bicyclic heterocyclic derivatives as Smo antagonists. WO2010082044 ; 2010
57. Malancona S, Altamura S, Filocamo G, et al. Identification of MK-5710 ((8alphaS)-8alpha-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl] -N-(1-phenyl-1H-pyrazol-5-yl) hexahydroimidazo[1,5-alpha]pyrazine-7 (1H)-carboxamide), a potent smoothened antagonist for use in hedgehog pathway dependent malignancies, part 1. Bioorg Med Chem Lett 2011;21:4422-8
58. Kinzel O, Alfieri A, Altamura S, et al. Identification of MK-5710 ((8alphaS)-8alpha-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl] -N-(1-phenyl-1Hpyrazol-5-yl)hexahydroimidazo[1,5-alpha] pyrazine-7(1H)- carboxamide), a potent smoothened antagonist for use in hedgehog pathway dependent malignancies, part 2. Bioorg Med Chem Lett 2011;21:4429-35
59. Siena Biotech SPA. Hedgehog pathway antagonists and therapeutic applications thereof. WO2009074300 ; 2009
60. Ferruzzi P, Mennillo F, De Rosa A, et al. In vitro and in vivo characterization of a novel hedgehog signaling antagonist in human glioblastoma cell lines. Int J Cancer 2012;131:E33-44
61. Pfizer LLC. Pyridine-2-derivatives as smoothened receptor modulators. WO2012052948 ; 2012
62. Rohner A, Spilker ME, Lam JL, et al. Effective targeting of hedgehog signaling in a medulloblastoma model of PF-5274857, a potent and selective smoothened antagonist that penetrates the blood-brain barrier. Mol Cancer Ther 2012;11:57-65
63. Centre National de la Recherche Scientifique. N-acylthiourea and Nacylurea inhibitors of the hedgehog protein signalling pathway. WO2009130422 ; 2009
64. Manzetti F, Faure H, Roudaut H, et al. Virtual screening-based discovery and mechanistic characterization of the acylthiourea MRT-10 family of smoothened antagonists. Mol Pharm 2010;78:658-65
65. Solinas A, Faure H, Roudaut H, et al. Acylthiourea, acylurea, and acylquanidine derivatives with potent hedgehog inhibiting activity. J Med Chem 2012;55:1559-71
66. Centre National de la Recherche Scientifique. Acyl guanidine derivatives modulating the hedgehog protein signaling pathway. WO2011010013 ; 2011
67. Takeda Pharmaceutical Co. Ltd. Fused heterocyclic derivative and use thereof. WO2009107850 ; 2009
68. Ohashi T, Oguro Y, Tanaka T. Discovery of pyrrolo[3,2-c]quinolone-4-one derivatives as novel hedgehog signaling inhibitors. Bioorg Med Chem 2012; In Press
69. Ohashi T, Oguro Y, Tanaka T. Discovery of the investigation drug TAK-441, a pyrrolo[3,2-C]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. Bioorg Med Chem 2012;20:5507-17
70. Biosynergo. Cyclohexylamines, phenylamines and uses thereof. WO2010022159 ; 2010
71. Yang H, Xiang J, Wang N, et al. Converse conformational control of smoothened activity by structurally related small molecules. J Biol Chem 2009;284:20876-84
72. Che C, Li S, Yang B, et al. Synthesis and characterization of SANT-75 derivatives as hedgehog-pathway inhibitors. Beilstein J Org Chem 2012;8:841-9
73. Alla Chem, Inc. Antagonist of smoothened. US20110098291 ; 2011
74. Alla Chem LLC. Heterocyclic inhibitors of an HH-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an HH-signal system. US20110053915 ; 2011
75. Strand MF, Wilson SR, Dembinski JL, et al. A novel synthetic smoothened antagonist transiently inhibits pancreatic adenocarcinoma xenografts in a mouse model. PLoS One 2011;6:e19904
76. Curis, Inc. Hedgehog antagonists having zinc binding motifs. WO2012094328 ; 2012
77. Chun SG, Zhou W, Yee NS. Combined targeting of histone deacetylases and hedgehog signaling enhances cytotoxicity in pancreatic cancer. Cancer Biol Ther 2009;8:1328-39
78. The Johns Hopkins University, The Board of Trustees of the Leland Stanford Junior University. Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies. WO2009049258 ; 2009
79. Kim J, Lee JJ, Kim J. Arsenic antagonizes the hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA 2010;107:13432-7
80. Beauchamp EM, Ringer L, Bulut G. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking hedgehog/GLI pathway. J Clin Invest 2011;121:148-60
81. The Wistar Institute and The Trustees of the University of Pennsylvania. Compounds and methods for the prevention and treatment of cancer. WO2012054228 ;2012
82. Winkler JD, Isaacs AK, Xiang C, et al. Design, synthesis, and biological evaluation of estrone-derived hedgehog signaling inhibitor. Tetrahedron 2011;67:10261-6
83. Winkler JD, Isaacs A, Holderbaum L, et al. Design and synthesis of inhibitors of hedgehog signaling based on the alkaloid cyclopamine. Org Lett 2009;11:2824-7
84. NovoMedix, LLC. Furanyl compounds and the use thereof. WO2011156321 ; 2011
85. Beachy PA, Liu JO. Hedgehog pathway antagonists to treat disease. US20090203713 ; 2009
86. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell 2010;17:388-99
87. IRM LLC. Hedgehog pathway modulators. WO2010027746 ; 2010
88. Uckun FM, Qazi S. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas. Expert Rev Anticancer Ther 2010;10:1407-18
89. Abraxis Bioscience, LLC. Isoquinoline, quinolone, and quinazoline derivatives as inhibitors of hedgehog signaling. WO2010144586 ; 2010
90. Abraxis Bioscience, LLC. Pyridyl-triazine inhibitors of hedgehog signaling. WO2010144404 ; 2010
91. Selexagen Therapeutics, Inc. Hedgehog inhibitors. WO2011085128 ; 2011
92. Amgen Inc. Oxazole compounds, compositions and methods of use. US20110060011 ; 2011
93. Alla Chem, LLC. Imidazo[1,2-A] pyridine-2-yl-phenyl derivatives to be used in cancer treatment. WO2010129620 ; 2010
94. Medimmune LLC. Antibodies against sonic hedgehog homolog and uses thereof. WO2010032061 ; 2010
95. Goetz SC, Ocbina PJ, Anderson KV. The primary cilium as a hedgehog signal transduction machine. Methods Cell Biol 2009;94:199-222
96. Hassounah NB, Bunch TA, McDermott KM. Molecular pathways: The role of primary cilia in cancer progression and therapeutics with a focus on hedgehog signaling. Clin Cancer Res 2012;18:2429-35
97. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366:2180-8
98. Nachtergaele S, Mydock LK, Krishnan K, et al. Oxysterols are allosteric activators of the oncoprotein smoothened. Nat Chem Biol 2012;8:211-20
99. Rominger CM, Tiger Bee W-L, Copeland RA, et al. Evidence for allosteric interactions of antagonist binding the smoothened receptor. J Pharmacol Exp Ther 2009;329:995-1005